Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M N Saleh

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Cancer Research|October 15, 1991
Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humansM B Khazaeli, M N Saleh, T P Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2000
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumorsM N Saleh, S Sugarman, J Murray, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1992
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancerR F Meredith, M B Khazaeli, W E Plott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administrationR M Conry, M B Khazaeli, M N Saleh, et al.
Human Antibodies and Hybridomas|January 1, 1992
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanomaM N Saleh, M B Khazaeli, R H Wheeler, et al.
Blood|May 15, 1995
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factorM N Saleh, S J Goldman, A F LoBuglio, et al.
Blood|January 15, 1998
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2C F LeMaistre, M N Saleh, T M Kuzel, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiationM N Saleh, K P Raisch, M A Stackhouse, et al.
Journal of the American Academy of Dermatology|July 23, 1998
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesM N Saleh, C F LeMaistre, T M Kuzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerF Robert, M P Ezekiel, S A Spencer, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Cancer Research|October 15, 1991
Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humansM B Khazaeli, M N Saleh, T P Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2000
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumorsM N Saleh, S Sugarman, J Murray, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1992
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancerR F Meredith, M B Khazaeli, W E Plott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administrationR M Conry, M B Khazaeli, M N Saleh, et al.
Human Antibodies and Hybridomas|January 1, 1992
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanomaM N Saleh, M B Khazaeli, R H Wheeler, et al.
Blood|May 15, 1995
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factorM N Saleh, S J Goldman, A F LoBuglio, et al.
Blood|January 15, 1998
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2C F LeMaistre, M N Saleh, T M Kuzel, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiationM N Saleh, K P Raisch, M A Stackhouse, et al.
Journal of the American Academy of Dermatology|July 23, 1998
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesM N Saleh, C F LeMaistre, T M Kuzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerF Robert, M P Ezekiel, S A Spencer, et al.
Pageof 5